Document Detail


Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial.
MedLine Citation:
PMID:  16702588     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Benznidazole is effective for treating acute-stage Chagas disease, but its effectiveness for treating indeterminate and chronic stages remains uncertain. OBJECTIVE: To compare long-term outcomes of patients with nonacute Chagas disease treated with benznidazole versus outcomes of those who did not receive treatment. DESIGN: Clinical trial with unblinded, nonrandom assignment of patients to intervention or control groups. SETTING: Chagas disease center in Buenos Aires, Argentina. PATIENTS: 566 patients 30 to 50 years of age with 3 positive results on serologic tests and without heart failure. MEASUREMENTS: The primary outcome was disease progression, defined as a change to a more advanced Kuschnir group or death. Secondary outcomes included new abnormalities on electrocardiography and serologic reactivity. INTERVENTION: Oral benznidazole, 5 mg/kg of body weight per day for 30 days (283 patients), or no treatment (283 patients). RESULTS: Fewer treated patients had progression of disease (12 of 283 [4%] vs. 40 of 283 [14%]; adjusted hazard ratio, 0.24 [95% CI, 0.10 to 0.59]; P = 0.002) or developed abnormalities on electrocardiography (15 of 283 [5%] vs. 45 of 283 [16%]; adjusted hazard ratio, 0.27 [CI, 0.13 to 0.57]; P = 0.001) compared with untreated patients. Left ventricular ejection fraction (hazard ratio, 0.97 [CI, 0.94 to 0.99]; P < 0.002) and left ventricular diastolic diameter (hazard ratio, 2.45 [CI, 1.53 to 3.95]; P < 0.001) were also associated with disease progression. Conversion to negative results on serologic testing was more frequent in treated patients than in untreated patients (32 of 218 [15%] vs. 12 of 212 [6%]; adjusted hazard ratio, 2.1 [CI, 1.06 to 4.06]; P = 0.034). LIMITATIONS: Nonrandom, unblinded treatment assignment was used, and follow-up data were missing for 20% of patients. Loss to follow-up was more common among patients who were less sick. Two uncontrolled interim analyses were conducted. CONCLUSIONS: Compared with no treatment, benznidazole treatment was associated with reduced progression of Chagas disease and increased negative seroconversion for patients presenting with nonacute disease and no heart failure. These observations indicate that a randomized, controlled trial should now be conducted.
Authors:
Rodolfo Viotti; Carlos Vigliano; Bruno Lococo; Graciela Bertocchi; Marcos Petti; María Gabriela Alvarez; Miriam Postan; Alejandro Armenti
Related Documents :
20381668 - Determinants of adiponectin levels in patients with chronic systolic heart failure.
939978 - Clinical radiosotope investigations in hydrosyringomyelia and myelodysplasia.
16514468 - 31p-mr spectroscopic imaging in hypertensive heart disease.
15200118 - Correlation between decreased ventricular size and positive clinical outcome following ...
6965448 - Regional enteritis with major gastrointestinal hemorrhage as the initial manifestation.
18299738 - Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achi...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Annals of internal medicine     Volume:  144     ISSN:  1539-3704     ISO Abbreviation:  Ann. Intern. Med.     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-05-16     Completed Date:  2006-05-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372351     Medline TA:  Ann Intern Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  724-34     Citation Subset:  AIM; IM    
Affiliation:
Hospital Interzonal General de Agudos Eva Perón and Instituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina. peron@millicom.com.ar
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Animals
Antibodies, Protozoan / blood
Chagas Cardiomyopathy / diagnosis*,  etiology
Chagas Disease / drug therapy*,  parasitology,  physiopathology
Chronic Disease
Disease Progression
Electrocardiography
Female
Follow-Up Studies
Humans
Male
Middle Aged
Nitroimidazoles / therapeutic use*
Prognosis
Sensitivity and Specificity
Trypanocidal Agents / therapeutic use*
Trypanosoma cruzi / immunology
Chemical
Reg. No./Substance:
0/Antibodies, Protozoan; 0/Nitroimidazoles; 0/Trypanocidal Agents; 22994-85-0/benzonidazole
Comments/Corrections
Comment In:
Ann Intern Med. 2006 May 16;144(10):772-4   [PMID:  16702594 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The sensitivity and specificity of a simple test to distinguish between urge and stress urinary inco...
Next Document:  Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver tran...